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The biosynthetic gene cluster for the aromatic polyketide steffimycin of the anthracycline family has been
cloned and characterized from “Streptomyces steffisburgensis” NRRL 3193. Sequence analysis of a 42.8-kbp DNA
region revealed the presence of 36 open reading frames (ORFs) (one of them incomplete), 24 of which,
spanning 26.5 kb, are probably involved in steffimycin biosynthesis. They code for all the activities required for
polyketide biosynthesis, tailoring, regulation, and resistance but show no evidence of genes involved in
L-rhamnose biosynthesis. The involvement of the cluster in steffimycin biosynthesis was confirmed by expres-
sion of a region of about 15 kb containing 15 ORFS, 11 of them forming part of the cluster, in the heterologous
host Streptomyces albus, allowing the isolation of a biosynthetic intermediate. In addition, the expression in S.
albus of the entire cluster, contained in a region of 34.8 kb, combined with the expression of plasmid pRHAM,
directing the biosynthesis of L-rhamnose, led to the production of steffimycin. Inactivation of the stfX gene,
coding for a putative cyclase, revealed that this enzymatic activity participates in the cyclization of the fourth
ring, making the final steps in the biosynthesis of the steffimycin aglycon similar to those in the biosynthesis
of jadomycin or rabelomycin. Inactivation of the stfG gene, coding for a putative glycosyltransferase involved
in the attachment of L-rhamnose, allowed the production of a new compound corresponding to the steffimycin
aglycon compound also observed in S. albus upon expression of the entire cluster.
Anthracycline antibiotics are aromatic polyketide com-
pounds widely used as therapeutics for the treatment of a
variety of cancers (37). Daunorubicin and doxorubicin were
the first identified anthracyclines, isolated from Streptomyces
spp. in the early 1960s, and remain clinically widely used today
as single agents or in adjuvant therapy in the treatment of
hematological and solid tumors, such as acute leukemia, high-
grade lymphoma, breast cancer, and bladder cancer. This has
prompted the study of this family of natural products to the
level of their biosynthesis in order to develop new bioactive
compounds by recombinant DNA technology (33). In particu-
lar, three anthracycline compounds have been studied so far:
daunorubicin-doxorubicin (18), nogalamycin (59, 56), and aclaci-
nomycin (42, 43). These studies have revealed the assembly of this
type of compound by type II polyketide synthases (PKS) that
consist of several discrete proteins carrying a set of iteratively
used enzyme activities.
Steffimycin (Fig. 1A) belongs to the anthracycline family of
compounds and contains in its structure several distinctive
characteristics not present in other anthracyclines: (i) the C-10
keto group, to which there is usually a carboxymethyl group
(nogalamycin and aclacinomycin) attached or neither substitu-
tion nor a functional group (daunorubicin); (ii) two methoxy
groups at C-2 and C-8 not present in nogalamycin, aclacino-
mycin, or daunorubicin; and (iii) a neutral deoxysugar instead
of the aminosugar normally attached to C-7 in other anthra-
cyclines. Steffimycin was isolated in 1967 as antibiotic U-20,661
(2) from “Streptomyces steffisburgensis,” which also produces
8-demethoxy steffimycins (23). Later, other members of this
subfamily of compounds were isolated: aranciamycin from
Streptomyces echinatus (19, 49); steffimycin B from Streptomy-
ces elgreteus (6), which produces in addition steffimycin and
steffimycin C (7); and finally steffimycin D from a Streptomyces
sp. (52).
Steffimycin was shown to be nontoxic in mice but highly
cytotoxic in mammalian cell cultures (44). However, it showed
a low inhibitory effect on the growth of mouse leukemia L1210
(32) and P388 cells (57). Nevertheless, steffimycin was recently
shown to induce a high apoptotic response in HCT116 colon
carcinoma cells expressing p53 by inducing DNA damage (12).
In addition, steffimycin D derivatives inhibit the growth of ras
oncogene-expressed cells (52), steffimycin B analogues con-
taining chemical modification in C-3 are highly active against
mouse leukemia P388 cells (57), and aranciamycin derivatives
were found to inhibit DNA synthesis of Yoshida sarcoma tu-
mor cells (4).
Here, we report the cloning and characterization of the gene
cluster for steffimycin biosynthesis from “Streptomyces steffis-
burgensis” NRRL 3193. Heterologous expression in Streptomy-
ces albus and disruption experiments showed the involvement of
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the gene cluster in the biosynthesis of steffimycin, leading to the
isolation and characterization of three biosynthetic intermediates.
One of them allowed the identification of a mode for the cycli-
zation of the fourth ring different than that previously described
for the biosynthesis of other anthracyclines, such as nogalamycin
or daunorubicin, where an intermediate containing a carboxy-
methyl group at C-10 is required, and similar to that described for
the biosynthesis of the angucyclines jadomycin and rabelomycin.
In addition, the steffimycin gene cluster provides new enzymatic
tools for the modification of other anthracyclines for the gener-
ation of novel anticancer compounds.
MATERIALS AND METHODS
Strains, culture conditions, and plasmids. “Streptomyces steffisburgensis”
NRRL 3193, the steffimycin producer, and mutants were routinely grown on tryp-
tone soy broth. For protoplast formation, they were grown on R5 liquid medium
(21). Regeneration of protoplasts after transformation was carried out on solid R5
agar plates using standard procedures (21); after regeneration, clones were grown on
agar plates containing A medium for sporulation (14). Streptomyces albus J1074 (8)
was used as a host for expression of steffimycin genes. Escherichia coli DH10B
(Invitrogen) and ET12567 (28) were used for subcloning. Escherichia coli ED8767
(38) was used to propagate a cosmid library.
Plasmids pOJ260 (3) and pEM4 (41) were used for gene replacement and gene
expression, respectively. pBLUNT (Invitrogen) was used for cloning of PCR
products. pFBA and pLHyg were used as donors of the apramycin resistance
gene aac(3)IV and the hygromycin resistance gene hyg, respectively (26, 39).
pKC505 (45) was used to construct a cosmid library. pRHAM was used for
expression in S. albus as a source of genes coding for enzymes involved in
L-rhamnose biosynthesis (46). When antibiotic selection of transformants was
needed, 100 g/ml ampicillin, 20 g/ml tobramycin, 25 g/ml apramycin, 50
g/ml thiostrepton, or 50 g/ml hygromycin was used.
DNA manipulation. DNA manipulations were performed according to stan-
dard procedures for E. coli (47) and for Streptomyces (21). A cosmid library of “S.
steffisburgensis” genomic DNA was constructed in pKC505 according to proce-
dures published in the literature (45). Ligations were in vitro packaged using the
Gigapack III Gold packaging extract kit according to the manufacturer’s hand-
book (Stratagene). A number of the resulting E. coli transductants were picked
and transferred to 96-well microtiter plates containing Luria broth medium and
100 g/ml ampicillin. Clones were replica plated onto Luria agar plates contain-
ing ampicillin. After overnight growth at 37°C, colonies were transferred to nylon
membrane filters for in situ colony hybridization analysis according to published
methods (47) and screened using a labeled probe that was generated using the
DIG DNA labeling and detection kit (Roche).
Isolation of the steffimycin gene cluster. In order to generate a mutant defec-
tive in steffimycin production, we used a sequence coding for a ketoacyl synthase
(KS) from “S. steffisburgensis” present in the databases under accession no.
ABO24979. An internal fragment encompassing nucleotides 352 to 995 was
FIG. 1. (A) Structure of steffimycin. (B) Genetic organization of the steffimycin biosynthesis gene cluster. White arrows, genes not involved in
steffimycin biosynthesis; gray arrows, genes involved in steffimycin biosynthesis. The gray box represents the 2.9-kb HindIII-BamHI fragment used
as a probe for cosmid library screening. KSEH, STFa, Stf2B3, and Stf3E5 represent DNA regions present in plasmids pEM4KSEH and pEM4STFa
and in cosmids Stf2B3 and Stf3E5, respectively. (C) HPLC analysis of S. albus strains STFaC (containing pEM4STFa and pEM4) and STFaRHAM
(containing pEM4STFa and pRHAM). Peaks 3, 4, 5, 6, and STF correspond to compounds in Fig. 4. AU, arbitrary units; B, BamHI; H, HindIII;
Sn, SnaBI; Ev, EcoRV; STF, steffimycin.
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obtained by PCR from “S. steffisburgensis” total DNA using the oligoprimers
KSSTEFI (5-TTTAAGCTTACCTGGCAGGTCTCCGAGG-3; the HindIII
site is underlined) and KSSTEFII (5-AGAATTCATGGAGCTGACCGGTGT
CCG-3; the EcoRI site is underlined). The PCR conditions used were 97°C for
5 min; 30 cycles of 95°C for 30 s, 65°C for 45 s, and 72°C for 1 min; and a final
extension cycle at 72°C for 10 min. Pfx DNA polymerase (Invitrogen) and 2.5%
dimethylsulfoxide (DMSO) were used for all amplifications. A PCR product of
643 bp was cloned into HindIII-EcoRI-digested pOJ260 to obtain plasmid
pOJKS, which was introduced into “S. steffisburgensis” by protoplast transforma-
tion, and transformants were selected with apramycin. Southern analysis of the
mutant strain was performed using pOJKS as a probe.
Isolation of flanking DNA regions surrounding the KS was achieved by HindIII
and EcoRI digestions (in two separate reactions) of total DNA recovered from
the mutant strain. Religation of each digestion and transformation into E. coli
DH10B rendered two pOJ260 derivatives containing approximately 7.5 kb each,
pOJKSH (from HindIII digestion and religation) and pOJKSE (from EcoRI
digestion and religation). To recover the inserts, pOJKSH was digested with
PstI-HindIII and pOJKSE was digested with PstI-EcoRI, and both fragments
were cloned together into pEM4 digested with EcoRI-HindIII. The resultant
plasmid, pEM4KSEH, was used for expression in S. albus and for sequencing. A
2.9-kb HindIII-BamHI fragment isolated from pOJKSH was used as a probe for
cosmid library screening (Fig. 1B and 2C).
DNA sequencing and analysis. DNA sequencing was performed on double-
stranded DNA templates by the dideoxynucleotide chain termination method
(48) with the Cy5 Autocycle Sequencing Kit (Pharmacia Biotech); an Alf-express
automatic DNA sequencer (Pharmacia) was used. Computer-aided database
searching and sequence analysis were carried out with the University of Wiscon-
sin Genetics Computer Group software (9) and the BLAST program (1).
Cloning of the steffimycin gene cluster. In order to clone the entire steffimycin
gene cluster in a single construct, pEM4KSEH was digested with HindIII and
EcoRV that cut within stfMIII and within the thiostrepton resistance gene in pEM4,
respectively. Then, a 19.7-kb HindIII-EcoRV fragment from cosmid Stf2B3, con-
taining from the StfMIII C-terminal coding region to orf30, was subcloned into
pEM4KSEH digested with HindIII-EcoRV, generating pEM4STF. In this construct,
all genes from orf1 to orf30 were present, with orf30 incomplete. pEM4STF lacks a
portion of the thiostrepton resistance gene, making selection in Streptomyces impos-
sible. To solve this, a 1.6-kb EcoRV-SmaI fragment from pFBA (26) containing the
apramycin resistance gene aac(3)IV was subcloned into EcoRV-digested pEM4STF,
leading to pEM4STFa. This final construct, pEM4STFa, was used for heterologous
expression in S. albus, together with pEM4 (41) or pRHAM (46).
Inactivation of stfX and stfG. The stfX gene was inactivated by SnaBI digestion
of pEM4KSEH and cloning of the hyg gene (in the same direction as stfX) from
EcoRV-digested pLHyg. The resultant construct, pEM4KSEHX-Hyg, was used
for expression in S. albus to verify metabolite production.
To inactivate the stfG gene, an internal fragment of 442 bp was amplified by
PCR from “S. steffisburgensis” total DNA using oligoprimers G3 (5-CTGCTG
TGGGGGCCGGATCTCTTC-3) and G4 (5-CGCCGAGGGAGATGCGAT
CCGGAT-3). The PCR conditions used were 97°C for 5 min; 15 cycles of 95°C
for 30 s, 70°C to 55°C for 45 s, and 72°C for 1 min; 15 cycles of 95°C for 30 s, 63°C
for 45 s, and 72°C for 1 min; and a final extension cycle at 72°C for 10 min. The
PCR product was cloned into pBLUNT. The resultant plasmid was digested with
EcoRI, and the fragment was cloned into pOJ260 to obtain plasmid pOJG, which
FIG. 2. (A) Strategy to generate mutant M1KS in “S. steffisburgensis.” The black and gray boxes represent the PCR-amplified fragments used
for disruption and the same region in the “S. steffisburgensis” chromosome, respectively. (B) HPLC analysis of “S. steffisburgensis” wild type (wt)
and strain M1KS. Peaks 4, 5, 6, and STF correspond to compounds in Fig. 4. (C) Strategy for recovery of the KS DNA flanking region. The dashed
box represents the 2.9-kb HindIII-BamHI fragment used as a probe for cosmid library screening. aac(3)IV, apramycin resistance gene; AU,
arbitrary units; STF, steffimycin.
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was introduced into “S. steffisburgensis” by protoplast transformation, and trans-
formants were selected with apramycin. Southern analysis of the mutant strain
(strain OJG) was performed using pOJG as a probe.
Analysis of steffimycin production by HPLC and liquid chromatography (LC)-
mass spectrometry. Steffimycin production was assessed qualitatively by growing
the “S. steffisburgensis” wild-type strain, mutants, or S. albus expressing pEM4
derivatives on solid R5A medium. After 5 days at 30°C, agar plugs containing 1.5
ml of agar media were extracted with 1 ml ethyl acetate, and the presence of
steffimycin in the extract was analyzed by high-performance liquid chromatrog-
raphy (HPLC) as described below. In liquid cultures, strains were grown as a
seed culture in tryptone soy broth (30 ml in a 250-ml Erlenmeyer flask). After 2
days of incubation in a rotary incubator (30°C; 250 rpm), 2.5% (vol/vol) of the
cultures were used to inoculate 30 ml of R5A liquid medium. After 5 additional
days of incubation with shaking, the cultures were harvested for analysis; 1-ml
aliquots of fermentation broth were removed and adjusted to pH 3 by the
addition of 90% formic acid. Ethyl acetate (300 l) was added, and the sample
was then mixed vigorously for 30 min. The phases were separated by centrifu-
gation in a microcentrifuge, and then the ethyl acetate was removed by evapo-
ration using a Speed-Vac. Residues were resuspended in methanol and clarified
by centrifugation. Analysis of steffimycin production was performed by HPLC in
a reversed-phase column (Symmetry C18; 4.6 by 250 mm; Waters) with acetoni-
trile and 0.1% trifluoroacetic acid (TFA) in water as solvents. A linear gradient
from 10 to 100% acetonitrile in 30 min, at a flow rate of 1 ml/min, was used.
Detection and spectral characterization of peaks were performed with a photo-
diode array detector and Millennium software (Waters), and bidimensional
chromatograms were extracted at 433 nm.
LC-mass spectrometry analysis was performed in a Symmetry C18 column (2.1
by 150 mm; Waters) using an Alliance chromatographic module coupled with
a photodiode array detector 2996 and mass spectrometer ZQ4000 (Waters-
Micromass). The chromatographic conditions were as previously described
with a flow rate of 0.25 ml/min. Mass analysis was performed by electrospray
ionization (ESI) in positive mode, with a capillary voltage of 3 kV and cone
voltage of 20 V.
Isolation and physicochemical properties of the new intermediates of steffi-
mycin biosynthesis. Compounds 1 and 2 were purified from cultures of S. albus
carrying pEM4KSEHX-Hyg. The culture conditions were as described above.
Cultures were harvested by centrifugation (12,000 rpm; 30 min), and the super-
natant was filtered using a 1-m Mini Profile cartridge (Pall). The filtrated broth
was solid phase extracted (SepPak C18; 10 g; Waters) and then eluted by a linear
gradient of methanol and 0.1% TFA in water (0 to 100% in 30 min at a flow rate
of 10 ml/min), taking fractions every 5 min. Fractions containing compound 1 or
2 were concentrated by evaporation using a rotavapor after the addition of 10 ml
0.1 M phosphate buffer (pH 7.0). The extracts were dissolved in 5 ml DMSO-
methanol (50:50) and then chromatographed in a Bondapak C18 cartridge
(PrepPak; 25 by 100 mm; Waters) via isocratic elution with acetonitrile and 0.1%
TFA in water (55:45) at 10 ml/min. Pure compounds were solid phase extracted
to remove the acid; 20.8 mg of compound 1 and 32 mg of compound 2 were
recovered from 5-liter cultures.
The structures of the new compounds 1 and 2 were elucidated by nuclear
magnetic resonance (NMR) spectroscopy and mass spectrometry. The ESI mass
spectra (ESI-MS) were acquired using a Finnigan LCQ mass spectrometer. The
electron impact (EI) ionization mass spectra were measured using a Finnigan
PolarisQ mass spectrometer. The high-resolution EI ionization mass spectra
were recorded at 25 eV on a JEOL JMS-700T M station (magnetic-sector
instrument) at a resolution greater than 10,000. The UV spectra were recorded
on a Varian model CARY50 spectrophotometer. All NMR data were recorded
in (d5-pyridine using either a Varian Mercury 300 or a Varian Inova 400 MHz
spectrometer. All NMR assignments were confirmed by heteronuclear single
quantum correlation and heteronuclear multiple bond correlation spectra, al-
lowing an unambiguous assignment of all signals.
Nucleotide sequence accession number. The sequence of the insert in
pEM4KSEH and cosmid Stf2B3 (700-bp overlapping region; 42,877 bp) was
deposited in the EMBL database under accession number AM156932.
RESULTS AND DISCUSSION
Isolation and characterization of the steffimycin gene clus-
ter. For the isolation of the steffimycin gene cluster, we took
advantage of a DNA sequence from “S. steffisburgensis” avail-
able from the databases (accession no. ABO24979) coding for
part of a KS. BLAST analysis of the deduced partial protein
coded by this DNA sequence showed high similarities to KSs
involved in the biosynthesis of different type II aromatic
polyketides. In particular, the best match corresponded to
Snoa1 (76% identity, 86% similarity), involved in the biosyn-
thesis of nogalamycin (59). With this information, a PCR frag-
ment was amplified from “S. steffisburgensis” total DNA, veri-
fied by DNA sequencing to contain KS-like amino acid
sequences, and cloned into pOJ260 generating pOJKS (Fig.
2A). This construct in a Streptomyces suicide vector was used
for gene disruption experiments in order to generate a non-
producing mutant. After transformation of “S. steffisburgensis”
protoplasts, apramycin-resistant colonies were selected and an-
alyzed for steffimycin production by LC-mass spectrometry. All
isolated colonies were found to correspond to nonproducing
mutants, and one of them (M1KS) (Fig. 2B) was selected for
further studies. The correct insertion in the “S. steffisburgensis”
chromosome was verified by Southern hybridization using the
PCR product as a probe (data not shown).
Once the region containing the steffimycin gene cluster was
identified, digestions and religations of total DNA from the
mutant strain (as described in Materials and Methods) allowed
the recovery of plasmid pOJ260 containing chromosomal-
DNA fragments adjacent to the point of insertion and covering
15 kb in two fragments of approximately 7.5 kb each (pOJKSE
and pOJKSH). The inserts in these constructs were cloned
together, leading to plasmid pEM4KSEH (Fig. 2C).
Expression of pEM4KSEH in S. albus led to the production
of a red compound with an HPLC retention time of 17.9 min
and a mass of 357 m/z ([MH]), which might correspond to 2-
O-demethyl-8-demethoxy-10-deoxysteffimycinone (compound 1)
(Fig. 3B). Compound 1 was converted to steffimycin when fed
to the “S. steffisburgensis” M1KS mutant (data not shown),
confirming this compound as an intermediate of steffimycin
biosynthesis.
Preliminary partial sequencing of the insert pEM4KSEH
showed a region of approximately 4 kb presumably not in-
volved in steffimycin biosynthesis at the EcoRI side of the
insert. The remaining 11 kb of the insert contained genes
possibly involved in the biosynthesis of steffimycin.
The insert in pOJKSH was used as a probe to screen a
cosmid library of “S. steffisburgensis” chromosomal DNA.
Three overlapping positive cosmid clones (Stf2B3, Stf2D7, and
Stf3E5) were isolated. The insert in pEM4KSEH and cosmid
Stf2B3 (700-bp overlapping region) were sequenced.
Analysis of the sequence for open reading frames (ORFs)
and alignment with related sequences in databases revealed
the presence of 36 ORFs (one of them incomplete). Of these,
24 ORFs (covering a region of 26.5 kb) are probably involved
in steffimycin biosynthesis as structural, regulatory, and resis-
tance genes and are flanked by 12 ORFs containing genes
involved in primary metabolism and housekeeping genes (Fig.
1B and Table 1).
Several ORFs (orf1 to orf4 and orf33 to orf36) showed by
BLAST analysis significant similarities to related proteins from
Streptomyces coelicolor A3(2) and Streptomyces avermitilis MA-
4680. Interestingly, they also share the same genetic organiza-
tion. Other ORFs (orf29 to orf32) did not show similarities to
proteins in databases that would suggest a role for these pro-
teins in steffimycin biosynthesis (Table 1 and Fig. 1B).
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Genes encoding a type II polyketide synthase and related
genes. Biosynthesis of anthracyclines begins with the conden-
sation of small carboxylic acids by the iterative action of a type
II PKS composed of two ketosynthases (KS and KS, also
known as chain length factor [CLF]) and an acyl carrier pro-
tein. Once the polyketide backbone is formed, different keto-
reductases (KR), cyclases (CYC), aromatases, and oxygenases
take actions to fold and decorate the polyketide into an aro-
matic compound.
Biosynthesis of steffimycin resembles in the initial steps that
of other anthracycline antibiotics previously described. In par-
ticular, steffimycin biosynthesis mimics nogalamycin biosynthe-
sis from 10 acetates up until the formation of 2-hydroxyl-
nogalonic acid (compound 2) (Fig. 4). However, they differ in
the absence of a polyketide reductase, a homologue of SnoaD,
responsible for the lack of a C-2 hydroxyl group in nogalamycin
(23, 17), a residue present in steffimycin (Fig. 1A).
In the steffimycin cluster, stfP, stfK, and stfS code for the
minimal PKS. Then, aromatization of the first ring would likely
be performed by the stfQ product and cyclization of the second
and third rings by the stfY product, and the stfOI gene would
code for an oxygenase involved in anthrone oxygenation at
C-12. These functions are proposed based on the high degree
of similarity of these products to similar enzymes present in
databases and involved in the biosynthesis of different anthra-
cyclines (aclacinomycin, daunorrubicin, nogalamycin, and rhodo-
mycin) and related compounds (chartreusin, chromomycin A3,
mithramycin, and simocyclinone) (Table 1).
At this point, cyclization to the fourth ring takes place,
apparently by a different mechanism. In the biosynthesis of
nogalamycin and daunorubicin, at least three activities are
required to transform nogalonic acid to nogalaviketone or
aklanonic acid to aklaviketone. The C-10 carboxyl-methyl trans-
ferases SnoaC/DnrC (17, 29), the nogalonic-aklanonic acid
methyl ester cyclases SnoaL/DnrD (51, 20), and homologues of
ActVI-ORFA, SnoO/DpsH, with an unclear function (17, 16),
are required for cyclization (Fig. 5). However, in the equivalent
steps in steffimycin biosynthesis (to transform compound 2 into
compound 1), only one activity is probably required (Fig. 4 and
5). StfX, due to its homology to SnoO (Table 1), DnrH, MtmX,
and CmmX, and also based on disruption experiments (see
below), corresponds to a CYC likely involved in the closure of
the fourth ring.
Finally, a C-7 KR, coded by stfT, similar to SnoaF/DnrE (17,
18), reduces the C-7 keto group (Fig. 4 and 5). In daunorubicin
biosynthesis, an additional step catalyzed by the DnrP esterase
FIG. 3. HPLC analysis of S. albus expressing pEM4 (A), pEM4KSEH (B), and pEM4KSEHX-Hyg (C) and the products accumulated (1 and
2). AU, arbitrary units.
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is required to remove the carboxymethyl group at C-10 after
glycosylation (29, 10).
Since 2-O-demethyl-8-demethoxy-10-deoxysteffimycinone
(compound 1) was isolated from S. albus expressing pEM4KSEH,
which contains the stfPKS (minPKS), stfQ (aromatase), stfY
(CYC), stfOI (oxygenase), stfX, and stfT (C7 KR) genes (Fig. 3
and 4), this implies that activities encoded by those genes are
sufficient for biosynthesis of compound 1, with StfX as the unique
candidate for cyclization of the fourth ring. In addition, it dem-
onstrates that methylesterification of the carboxyl group is not
required to activate the cyclization reaction, as in daunorubicin
biosynthesis (20).
Post-PKS genes. The next step in the biosynthesis of steffi-
mycin is a C-2-O methylation accomplished by an O-methyl-
transferase, leading to 8-demethoxy-10-deoxysteffimycinone
(compound 3), which might be the substrate for the glycosyl-
tranferase (Fig. 4). There are three genes in the cluster coding
for O-methyltransferases, stfMI, stfMII, and stfMIII. Based on
the similarities shown in Table 1, StfMII could be the methyl-
transferase responsible for methylation of the C-2 hydroxyl
TABLE 1. Proposed functions of deduced steffimycin gene cluster products
ORF No. ofaaa
Proposed function in steffimycin
biosynthesis Closest similar protein, origin, (% identity/similarity), accession no.
orf1 483 Putative IMP dehydrogenase SCL6.18c, S. coelicolor A3(2), (91/96), CAB76883
orf2 117 Hypothetical protein SCL6.19c, S. coelicolor A3(2), (78/89), CAB76884
orf3 347 Putative transcriptional regulator SCL6.20c, S. coelicolor A3(2), (96/98), CAB76885
orf4 228 Ribulose-phosphate 3-epimerase SCL6.21c, S. coelicolor A3(2), (95/98), CAB76886
sfrA 712 Transmembrane efflux protein Putative membrane protein similar to ActII-3 SAV6879, Streptomyces avermitilis MA-
4680, (76/86), BAC74590
stfS 86 Acyl carrier protein Acyl carrier protein NcnC, Streptomyces arenae DSM40737, (64/80), AAD20269
stfK 406 Chain length factor Ketosynthase  Snoa2, Streptomyces nogalater ATCC 27451, (72/81), CAA12018
stfP 422 Ketoacyl synthase Ketosynthase, “Streptomyces steffisburgensis” JCM 4833T, (98/98), BAA92281
stfOI 111 Monooxygenase Oxygenase SnoaB, Streptomyces nogalater ATCC 27451, (47,65), CAA12015
stfT 274 C-7 ketoreductase Ketoreductase ChaL, Streptomyces chartreuses HKI-249, (46/72), CAH10174
stfX 146 Fourth-ring cyclase SnoO, Streptomyces nogalater ATCC 27451, (52/62), AAF01807
stfY 259 Second- and third-ring cyclase Putative polyketide cyclase SnoaM, Streptomyces nogalater ATCC 27451, (74/83),
AAF01818
stfRI 290 SARP family regulator Putative SARP family pathway-specific regulatory protein ORF71, Streptomyces rochei
7434AN4, (55/73), BAC76529
stfRII 196 Putative transcriptional regulator Putative two-component response regulator Gra-orf10, Streptomyces violaceoruber
Tu22, (49/69), CAA09631
stfQ 309 Aromatase Putative aromatase SAV2383, Streptomyces avermitilis MA-4680, (51/63), BAC70094
stfMI 225 O-Methyltransferase Putative O-methyltransferase EncK, Streptomyces maritimus, (40/59), AAF81726
stfC 187 Unknown SWIM Zn finger Franean1DRAFT_6984, Frankia sp. strain EAN1pec, (56/70),
ZP_00567311
stfD 618 Unknown SNF2-related domain:helicase, C-terminal Franean1DRAFT_6983, Frankia sp. strain
EAN1pec, (72/81), ZP_00567310
sfrB 502 Transmembrane efflux protein Putative transmembrane efflux protein SCE22.16c, Streptomyces coelicolor A3(2),
(41/61), CAB90983
stfRIII 116 Putative transcriptional regulator Hypothetical DNA-binding protein YcgE, Bacillus licheniformis ATCC 14580, (31/59),
AAU23698
stfPI 402 Monooxygenase Cytochrome P450 Franean1DRAFT_4258, Frankia sp. strain EAN1pec, (46/59),
ZP_00570217
stfE 526 Dehydrogenase BusJ, Saccharopolyspora pogona NRRL 30141, (55/68), AAY88927
stfOII 387 Monooxygenase Possible dioxygenase Mb3186c, Mycobacterium bovis AF2122/97, (51/64), NP_856831
stfMII 391 O-Methyltransferase Putative O-methylase SnogY, Streptomyces nogalater ATCC 27451, (54/68), CAA12021
stfF 113 Unknown 5-Chloromuconolactone dehalogenase ClcF, Rhodococcus opacus 1CP, (38/66),
CAD28145
stfG 420 Glycosyltransferase Putative glycosyltransferase SnogE, Streptomyces nogalater ATCC 27451, (62/74),
AAF01809
stfPII 366 Cytochrome P450-like Protein similar to DnmQ AknT, Streptomyces galilaeus ATCC 31615, (36/47),
AAF73456
stfMIII 392 O-Methyltransferase Methyltransferase MycE, Micromonospora griseorubida, (42/58), BAC57026
orf29 1,404 Hypothetical protein SAV4434, S. avermitilis MA-4680, (37/49), NP_825611
orf30 374 Hypothetical protein FG11565.1, Gibberella zeae PH-1, (41/57), EAA78433
orf31 344 Trypsin-like serine proteases Npun02003978, Nostoc punctiforme PCC 73102, (35/51),
ZP_00110193
orf32 415 Uncharacterized protein conserved in bacteria PphaDRAFT_1502, Pelodictyon
phaeoclathratiforme BU-1, (41/57), ZP_00590365
orf33 475 Conserved hypothetical Sun-family protein SCL6.29c, S. coelicolor A3(2), (90/95),
CAB76894
orf34 310 Methionyl-tRNA formyltransferase SCL6.30c, S. coelicolor A3(2), (89/95), CAB76895
orf35 183 Hypothetical protein SAV6876, S. avermitilis MA-4680, (88/91), BAC74587
orf36 422b Putative primosomal protein N SCL6.32c, S. coelicolor A3(2), (86/90), CAB76897
a Number of amino acids of the deduced protein.
b Incomplete.
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group in L-rhamnose, since its close homologue, SnogY, is
involved in the methylation of the deoxysugar L-nogalose (56).
StfMI and StfMIII might be involved in O methylation of the
2- and 8-hydroxyl groups, respectively, since coexpression of
pEM4KSEH (stfMI incomplete) and cosmid Stf3E5 (Fig. 1B)
in S. albus leads to production of compound 3 (Fig. 4), while
coexpression of pEM4KSEH and cosmid Stf2B3 (stfMI incom-
plete) (Fig. 1B) leads to production of compound 1 (Fig. 4 and
data not shown).
Two genes are involved in the attachment of the sugar moi-
ety L-rhamnose, stfG and stfPII. StfG homologues are well-
known glycosyltransferases involved in the biosynthesis of
other anthracyclines. StfPII resembles cytochromes P450 that
lack the conserved Cys necessary to bind the heme prosthetic
group. The roles of several enzymes belonging to that class of
cytochromes, AknT (27), EryCII (60), and DesVIII (5), have
been recently unraveled as proteins needed to activate their
counterpart glycosyltransferases (AknS, EryCI, and DesVII)
during the process of glycosylation.
Another aspect of the glycosylation process is the total ab-
sence of sugar biosynthesis genes in the cluster. This seems to
be a general feature of all gene clusters containing L-rhamnose
so far characterized, such as elloramycin (A. Ramos, unpub-
lished results) and spinosyn (58). Whether those genes are
shared for steffimycin and cell wall biosyntheses, as in S. spi-
nosa (30), remains to be addressed.
After glycosylation of compound 3, late steps in steffimycin
biosynthesis involve 2-O methylation of L-rhamnose (probably by
StfMII) and oxidation of C-10 to a keto group (probably by
cytochrome P450 StfPI and dehydrogenase StfE), followed by
introduction of the 8-methoxy group (likely by StfOII and
StfMIII) (Fig. 4). Although there is no experimental evidence
of those steps being catalyzed by the enzymes described, the
sequence of events might be as shown, since compounds 8-de-
methoxy-2-demethyl-steffimycin D (compound 4), 8-demethoxy-
steffimycin D (compound 5), and 8-demethoxy-steffimycin (com-
pound 6) (Fig. 2B and 4) have been previously characterized (24).
Those compounds were also detected by LC-mass spectrometry
from cultures of “S. steffisburgensis” during the development of
this work (data not shown).
Regulatory and resistance genes. Three putative regulatory
genes are located in the steffimycin gene cluster (stfRI, stfRII,
and stfRIII).
StfRI is similar to a variety of pathway-specific Streptomyces
antibiotic regulatory proteins (SARP) (Table 1), including
DnrI from Streptomyces peucetius (54). StfRII resembles sev-
eral putative regulatory proteins similar to two-component re-
sponse regulators (Table 1), such as DnrN from S. peucetius.
StfRII might be essential for transcription of StfRI, as DnrN
controls the expression of the pathway-specific transcriptional
factor DnrI involved in daunorubicin biosynthesis (15). As in
S. peucetius (40, 15), no putative sensor kinase gene (usually
FIG. 4. Proposed pathway for the biosynthesis of steffimycin.
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located near the response regulator gene) was found in the
steffimycin gene cluster. However, an upper level of regulation
by the pleiotropic regulatory gene bldA that encodes tRNA-
Leu (24) might be involved in steffimycin production, since
there is one TTA codon in stfRI and two in stfRII.
A third regulatory protein, StfRIII, with similarity to DNA-
binding proteins (Table 1) and to putative regulatory proteins
of the MarR family (pfam01047) from S. coelicolor and S.
avermitilis, is also present in the cluster. Whether StfRIII is
involved in regulation of steffimycin biosynthesis or resistance
remains to be determined, since MarR proteins are usually
involved in antibiotic resistance as repressors and are also
multidrug-binding proteins whose repressor activities are af-
fected by their interactions with different compounds (50).
Two genes in the cluster (sfrA and sfrB) are candidates to be
involved in steffimycin resistance. SfrA and SfrB are similar to
integral membrane proteins of the MMPL family (pfam03176)
and permeases of the major facilitator superfamily (MFS;
COG0477). They contain 12 and 14 putative membrane-span-
ning helices, respectively, and are probably involved in the
export of and self-resistance to steffimycin.
“S. steffisburgensis” shows resistance to at least 50 g/ml
steffimycin. S. albus expressing Stf2B3 (sfrB is present) is re-
sistant to 25 g/ml steffimycin, while S. albus expressing
pEM4KSEH (sfrA is present) shows no resistance to steffimy-
cin at all (data not shown). This result points to SfrB as the real
resistance determinant. However, cooperation between SfrB
and SfrA to confer the level of resistance observed in “S.
steffisburgensis” cannot be excluded.
Genes of unknown function. Three genes in the cluster code
for proteins whose alignment with proteins from databases
does not allow a suggestion of their roles in steffimycin biosyn-
thesis. The stfF gene product belongs to muconolactone delta-
isomerases (pfam02426), and its close homologue ClcF (Table
1) is a 5-chloromuconolactone dehalogenase that converts
5-chloromuconolactone to cis-dienelactone (36).
The stfC gene product shows similarity to hypothetical pro-
teins containing SWIM-like zinc-chelating domains (31). StfD
homologues are proteins of the SNF2 family defined by the
presence of a conserved motif called the SNF2 domain
(pfam00176). This domain is found in ATP-dependent pro-
teins involved in a variety of processes, including transcription,
regulation, DNA repair, DNA recombination, and chromatin
unwinding. It has been mentioned that in prokaryotes lacking
a SWIM domain in SWI2/SNF2 ATPases, a gene encoding a
SWIM domain-containing protein is located directly upstream
of the gene for a SWI2/SNF2 ATPase (31), as is the case for
stfD-stfC (SNF2 and SWIM proteins, respectively) in the stef-
fimycin cluster (Fig. 1B).
The involvement of StfD and StfC in resistance to steffimy-
cin, contributing as some kind of repair system analogous to
the UV repair system found in daunorubicin (25), mithramycin
(13), and chromomycin (34) gene clusters, might be possible
and remains to be addressed.
Heterologous expression of the steffimycin gene cluster in S.
albus. To definitively verify that the isolated cluster led to the
production of steffimycin, a new construct, pEM4STFa, was
generated in which all genes proposed to be involved in stef-
fimycin biosynthesis were included. Since no L-rhamnose bio-
synthesis genes were identified in the sequenced region,
pEM4STFa was introduced in S. albus, together with a second
plasmid, pRHAM, which is known to lead to the production of
FIG. 5. Comparison of cyclization of the fourth ring in the biosyntheses of different aromatic polyketides. (A) Nogalamycin (56) and
daunorubicin (18). (B) Steffimycin. (C) UWM6 in jadomycin and rabelomycin biosynthesis (22, 35).
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L-rhamnose (46), thus generating strain STFaRHAM. In a
control experiment, pEM4STFa and pEM4 were simulta-
neously introduced in S. albus, generating strain STFaC.
Analysis of products accumulated by S. albus STFaC (Fig.
1C) showed the production of a red compound with an HPLC
retention time of 21.25 min and a mass of 371 m/z ([MH]),
which might correspond to 8-demethoxy-10-deoxysteffimyci-
none, compound 3 (Fig. 4), probably steffimycin aglycon. No
glycosylated compounds were detected.
Cultures of S. albus STFaRHAM (Fig. 1C) showed the pro-
duction of a mixture of red compounds, the major one of which
corresponded to steffimycin, showing an HPLC mobility of 20.7
min and a mass of 575 m/z ([MH]). In addition, other
minor compounds were identified by LC-mass spectrometry
as compounds 4, 5, and 6 (Fig. 1C and 4) with mobilities of
18.7, 20.3, and 20.1 min and masses of 517, 531, and 545 m/z
([MH]), respectively. Compounds 4, 5, and 6 were pre-
viously detected by LC-mass spectrometry, as mentioned
above, in cultures of “S. steffisburgensis” (Fig. 2B). These
expression experiments clearly show the presence in the
sequenced steffimycin cluster of all the genes required for
the biosynthesis of the polyketide, the tailoring steps, and
decoration of the sugar moiety, with the exception of genes
coding for the enzymes involved in the biosynthesis of L-
rhamnose. In addition, plasmid pEM4STFa represents a
useful tool for the future development of steffimycin deriv-
atives containing different sugar moieties.
Inactivation of stfX and stfG. Two gene inactivation experi-
ments were performed, first, to determine if stfX is involved in
cyclization of the fourth ring of 2-hydroxy-nogalonic acid (com-
pound 2) (Fig. 4), and second, to isolate the substrate for
StfG-mediated glycosylation and to verify its correspondence
to the previously identified compound 3 in cultures of S. albus
strain STFaC (Fig. 1C).
stfX was inactivated in pEM4KSEH by insertion of a copy of
the hyg gene into a unique SnaBI site. pEM4KSEHX-Hyg was
expressed in S. albus, and the production of red compounds
was monitored in both liquid and solid media by LC-mass
spectrometry. In both media, the formation of compound 1
previously observed by expression of pEM4KSEH in S. albus
was detected. In addition, a new compound 2 with an HPLC
retention of 21.59 min and a mass of 399 m/z ([MH]), which
might correspond to 2-hydroxy-nogalonic acid (Fig. 3C), was
also identified. Compound 2 was also detected as a minor
compound in cultures of S. albus pEM4KSEH and of “S. steffis-
burgensis,” but in S. albus pEM4KSEHX-Hyg, the production
rose 30-fold while that of compound 1 remained constant.
These results are in agreement with previous results ob-
served by disruption of actVI-ORFA, involved in actinorhodin
biosynthesis by S. coelicolor (53), where it leads to the accu-
FIG. 6. (A) Strategy to generate a mutant in stfG. (B) HPLC analysis of “S. steffisburgensis” (top) and “S. steffisburgensis” OJG (bottom).
(C) Product accumulated by the mutant. aac(3)IV, apramycin resistance gene; AU, arbitrary units.
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mulation of possible biosynthetic intermediates with a gross
reduction in actinorhodin biosynthesis. The authors suggested
that ActVI-ORFA played a general role in stabilizing the mul-
ticomponent type II PKS complex, rather than in catalyzing the
ring formation itself (53). Our results point to a spontaneous
cyclization of the fourth ring, with the StfX protein facilitating
the process.
In the biosynthesis of the angucycline antibiotics jadomycin
and rabelomycin, cyclases JadI and PgaF catalyze an intramo-
lecular aldol condensation to form the fourth angular ring
concomitant with the removal of a carboxyl group (22, 35),
which leads to the common intermediate UWM6 (Fig. 5).
Apart from the similarities between the cyclization mecha-
nisms of steffimycin biosynthesis and UWM6 formation, there
is no significant similarity between StfX and JadI or PgaF,
probably due to the structures of the products of the enzymatic
reactions (anthracycline versus angucycline) and because JadI
and PgaF are also involved in third-ring cyclizations.
stfG was inactivated by gene disruption using plasmid pOJG
(Fig. 6). Cultures of “S. steffisburgensis” OJG revealed the
production, as expected, of compound 3 with a mobility of
21.25 min and a mass of 371 m/z ([MH]), which might
correspond to 8-demethoxy-10-deoxysteffimycinone (Fig. 4 and
6C). This compound was previously observed in cultures of S.
albus strain STFaC, in which no genes coding for enzymes
involved in L-rhamnose biosynthesis are present (Fig. 1C). No
glycosylated compounds were detected by LC-mass spectrom-
etry analysis. For further confirmation of compound 3 as an
intermediate in the biosynthesis of steffimycin, it was fed to “S.
steffisburgensis” strain M1KS, which was able to convert it to
steffimycin (data not shown). In addition, disruption of stfG
was complemented in trans by stfG expressed in pEM4, restor-
ing steffimycin production.
Structure elucidation of 2-O-demethyl-8-demethoxy-10-de-
oxysteffimycinone (compound 1) and 2-hydroxy-nogalonic acid
(compound 2). Compound 1 showed a molecular ion peak in
low-resolution EI-MS at m/z 356 [M]. The ESI-MS of com-
pound 1 displayed in the negative ion mode a molecular ion of
m/z 355 [M-H], suggesting a molecular mass of 356 g/mol.
The molecular formula was determined from high-resolution
EI-MS to be C19H16O7. The presence of the peri-hydroxy-
anthraquinone chromophore in compound 1 is in agreement with
the observed UV maximum at a max of 435 nm in the UV/
visible-light spectrum. The 1H NMR spectrum of compound 1
showed two typical signals of chelated OH groups at 	 13.11
and 12.49, one singlet at 	 7.77, and two meta-coupled aromatic
protons at 	 7.69 and 6.98. Furthermore, one proton-coupled
oxygen-bound carbon at 	 5.80, two pairs of methylene protons
at 	 3.18 and 3.12 and 	 2.71 and 2.42, and one methyl group
at 	 1.71 were identified. The 13C NMR of compound 1 re-
vealed the presence of 19 carbon atoms. The quaternary car-
bon signals at 	 191.2 and 182.3 could be assigned to two
carbonyl groups of a quinone system. The spectra showed
three aromatic methines at 	 121.6, 110.1, and 109.3 and nine
FIG. 7. (A) Nuclear Overhauser enhancement effects observed in ring A of structure 1 confirm the relative stereochemistry of the centers in
ring A, as shown. (B) Chemical structures of the closest relatives of 2-hydroxynogalonic acid (compound 2), 58B (55) and aklanonic acid (11).
(C) Tautomeric mixture of 2-hydroxynogalonic acid (compound 2) as evident from the 1H NMR spectrum (data for the minor tautomers are not
listed). Compounds 1 and 2 correspond to compounds in Fig. 4.
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aromatic or olefinic quaternary carbon atoms, three of which,
at 	 167.8, 166.2, and 162.1, could be assigned to aromatic
carbons connected to oxygen atoms. Furthermore, two signals
at 	 69.1 and 64.5 for aliphatic quaternary carbons connected
to oxygen atoms, two methylenes at 	 46.1 and 45.8, and one
methyl group at 	 30.8 were delivered. Searches in the Chem-
ical Abstract database produced no results, pointing to a new
metabolite. The structure of compound 1 was established, tak-
ing into consideration 1JC-H and
3JC-H long-range couplings
observed in the heteronuclear single quantum correlation and
the constant time inverse-detected gradient accordion re-
solved–heteronuclear multiple bond correlation spectra, re-
spectively, and by comparison of the spectral data with the
structurally related 8-demethoxy-2-demethyl-steffimycin D
(compound 4) (Fig. 4) (23). The stereochemistry of ring A was
deduced to be (7S, 9S), because of a missing nuclear Over-
hauser effect correlation between 7-H and 9-CH3, while 9-CH3
showed nuclear Overhauser effects with each of the H atoms of
the 8- and the 10-methylene groups (Fig. 7A). The absolute
stereochemistry was established through comparison with com-
pound 4. Schmidt-Ba¨se et al. determined the absolute config-
uration of steffimycin B by X ray (49). In this study, the con-
figurations of the stereocenters in ring A were established to be
7R, 8S, and 9S. The ring adopted a half-chair conformation
without an extra stabilizing intramolecular H bond from 9-OH
to 7-O (see the supplemental material).
Compound 2 accommodates the similarity of aklanonic acid’s
UV spectrum (max in methanol, 435, 287, and 258 nm.). It
showed in the negative ion mode of ESI a mass spectrum of an
[M-H] peak at m/z 397, corresponding to a molecular mass of
398 g/mol. The 1H NMR spectrum of compound 2 revealed
one sharp singlet at 	 8.21, two meta-coupled aromatic protons
at 	 7.69 (2.1 Hz) and 6.99 (2.1 Hz), and one olefinic proton at
	 6.31. Furthermore, one methylene group at 	 4.25 and CH3
protons at 	 2.07 were observed. The 13C NMR spectrum of
compound 2 exhibited five carbonyl carbons at 	 192.8, 190.7,
186.1, 182.0, and 173.0, with the chemical shift being consistent
with a COOH group. Furthermore, quaternary carbon atoms
attached to oxygen were observed at 	 168.3, 168.2, and 166.4,
with four sp2 methine carbons at 	 122.0, 110.9, 109.4, and
105.0, respectively, and six sp2 quaternary carbon atoms. Ad-
ditionally, one methylene group at 	 40.6 and one methyl signal
at 	 25.0 were observed.
Searching the resulting structure 2 gave no hits in Chemical
Abstracts. Therefore, compound 2 is new. Structure 2 was also
confirmed by comparison of the spectral data with the struc-
turally related aklanonic acid and compound 58B (Fig. 7B)
(11, 55). Compound 2 (2-hydroxy-nogalonic acid) differs from
aklanonic acid and from compound 58B in being a free acid
versus a methylcarboxylate and through its acetyl starter group
instead of a propionyl starter group (lower side chain). The
structure elucidation was complicated by the fact that compound
2 exists in an equilibrium of three tautomeric forms (Fig. 7C).
However, as is well known from simple 1,3-diketones, as well as
from aklanonic acid, the keto-enol equilibrium lies far on the enol
side. This is also evident for compound 2 from its 1H NMR data.
In conclusion, the isolation and characterization of the steffi-
mycin gene cluster and its heterologous expression in S. albus
provide a new tool for the generation of novel anthracycline
derivatives by combinatorial biosynthesis. The characterization
of this cluster has also provided new insights into the enzymatic
mechanisms for polyketide ring cyclization. In contrast to other
anthracyclines, for which two enzymes are required for cycli-
zation of the fourth ring, in the case of steffimycin, this cycli-
zation event can probably occur spontaneously, with the pres-
ence of the stfX product facilitating the process.
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